Table 4.

Pharmacokinetic parameters for glepaglutide and metabolites following intravenous infusion of 1 mg

		Individual analytes
Parameter	Glepaglutide	Parent	M1	M2
AUClast (h × pmol/L)	40,800 (35.3%) [15]	37,100 (38.8%) [15]	782 (103%) [15]	1580 (108%) [15]
AUCinf (h × pmol/L)	44,200 (33.7%) [13]	40,500 (39.8%) [12]	1010 (70.4%) [14]	2930 (59.3%) [9]
Cmax (pmol/L)	54,900 (46.3%) [15]	54,100 (46.9%) [15]	446 (84.5%) [15]	419 (79.9%) [15]
tmax (h), median (min-max)	0.42 (0.28–0.58) [15]	0.42 (0.28–0.58) [15]	0.63 (0.35–1.02) [15]	1.50 (1.25–3.00) [15]
t1/2,z (h), mean (SD)	10.4 (8.93) [13]	11.7 (8.10) [12]	1.2 (0.24) [15]	2.6 (0.90) [14]
CL (L/h)		5.72 (39.8%) [12]
Vss (L)		14.0 (120%) [12]
MRAUCinf			0.0260 (97.3%) [11]	0.0812 (94.2%) [8]

Geometric mean (CV%) is presented unless otherwise specified. Numbers in square brackets denote the number of subjects included in the analysis

AUC_inf area under the plasma concentration–time curve from time zero to infinity, AUC_last area under the plasma concentration–time curve from time zero to the time of the last measurable concentration, CL clearance, C_max maximum observed plasma concentration, CV coefficient of variation, h hours, max maximum, min minimum, MR_AUCinf metabolite: parent ratio based on AUC_inf, SD standard deviation, t_1/2,z apparent plasma terminal elimination half-life, t_max time of the maximum observed plasma concentration, V_ss volume of distribution at steady state